Nurix reports 83% response rate for blood cancer drug bexobrutideg in heavily pre-treated patients

Filed June 11, 2026 · Period ending June 11, 2026 · ~1 min read

Key Changes

• high

  Phase 1 trial showed 83% objective response rate in relapsed/refractory CLL/SLL patients with median 4 prior therapies, including 38% with BTK resistance mutations. Median progression-free survival reached 22.1 months.

  Item 7.01: Clinical Data verify on EDGAR →
• high

  In earlier-line patients previously treated with BTK inhibitors but not BCL-2 inhibitors, response rate was 92.9% with 18 of 19 patients remaining on treatment at data cutoff.

  Item 7.01: Cohort 5 verify on EDGAR →
• high

  In BTK inhibitor-naïve patients including 10 treatment-naïve patients, response rate was 84.2% with 19 of 20 patients still on treatment, suggesting potential for first-line use.

  Item 7.01: Cohort 15 verify on EDGAR →